Table 1.
Demographics of the renal insufficiency and control groups
| Renal insufficiency | Control | p-value | |
|---|---|---|---|
| Number of patients | N = 66 | N = 196 | |
| Age, yr. | 73.64 (67.8-81.0) | 69.91 (62.3-77.0) | 0.011 |
| Body mass index, kg/m2 | 23.31 (21.0-25.4) | 23.65 (21.0-25.7) | 0.482 |
| Diabetes Miletus, n (%) | 22 (33.3) | 38 (19.4) | 0.020 |
| Hypertension, n (%) | 43 (65.2) | 91 (46.4) | 0.008 |
| History of upper tract urothelial carcinoma, n (%) | 15 (22.7) | 2 (1.0) | <0.001 |
| Sex, n (%) | 0.281 | ||
| Male | 55 (83.3) | 151 (77.9) | |
| Female | 11 (16.7) | 45 (23.0) | |
| Pathologic T stage, n (%) | 0.339 | ||
| pT0 | 15 (22.7) | 30 (15.3) | |
| pT1 | 21 (31.8) | 73 (37.2) | |
| pT2 | 9 (13.6) | 39 (19.9) | |
| pT3-4 | 21 (31.8) | 54 (27.6) | |
| Pathologic N stage, n (%) | 0.925 | ||
| pNx and pN0 | 56 (84.8) | 170 (86.7) | |
| pN1 | 4 (6.1) | 10 (5.1) | |
| pN2 | 6 (9.1) | 16 (8.1) | |
| Histologic variants, n (%) | 10 (19.6) | 30 (18.1) | 0.805 |
| Lymphovascular invasion, n (%) | 17 (25.8) | 36 (18.5) | 0.203 |
| Concomitant carcinoma in situ, n (%) | 20 (30.3) | 82 (41.8) | 0.096 |
| ADJ chemotherapy, n (%) | 9 (13.6) | 30 (15.3) | 0.742 |
| Hemoglobin, g/dL | 12.04 (10.8-13.1) | 13.10 (11.9-14.3) | <0.001 |
| Potassium, mmol/L | 4.56 (4.3-4.8) | 4.20 (4.0-4.4) | <0.001 |
| Uric acid, mg/dL | 6.11 (5.4-7.1) | 5.17 (4.3-6.1) | <0.001 |
Data are presented as mean (standard deviation; interquartile range) unless otherwise indicated.
ADJ: adjuvant.